文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

长非编码 RNA HOXB-AS3 促进髓系细胞增殖，其高表达是急性髓系白血病和骨髓增生异常综合征患者的不良预后标志物。

Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.

机构信息

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Doctoral Degree Program in Translational Medicine, National Taiwan University and Academia Sinica, Taipei, Taiwan.

出版信息

BMC Cancer. 2019 Jun 24;19(1):617. doi: 10.1186/s12885-019-5822-y.

DOI:10.1186/s12885-019-5822-y
PMID:31234830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6591843/
Abstract

BACKGROUND: Long non-coding RNAs (lncRNAs) represent the majority of cellular transcripts and play pivotal roles in hematopoiesis. However, their clinical relevance in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains largely unknown. Here, we investigated the functions of HOXB-AS3, a lncRNA located at human HOXB cluster, in the myeloid cells, and analyzed the prognostic significances in patients with AML and MDS. METHODS: shRNAs were used to downregulate HOXB-AS3 in the cell lines and the effect was evaluated by quantitative polymerase chain reaction. The proliferation of the cell lines was illustrated by proliferation and BrdU flow assays. Further, we retrospectively analyzed the HOXB-AS3 expression in 193 patients with AML and 157 with MDS by microarray analysis, and evaluated its clinical importance. RESULTS: Downregulation of HOXB-AS3 suppressed cell proliferation. Mechanistically, HOXB-AS3 potentiated the expressions of several key factors in cell cycle progression and DNA replication without affecting the expressions of HOX genes. In AML, patients with higher HOXB-AS3 expression had shorter survival than those with lower HOXB-AS3 expression (median overall survival (OS), 17.7 months versus not reached, P <  0.0001; median relapse-free survival, 12.9 months versus not reached, P = 0.0070). In MDS, patients with higher HOXB-AS3 expression also had adverse prognosis compared with those with lower HOXB-AS3 expression (median OS, 14.6 months versus 42.4 months, P = 0.0018). The prognostic significance of HOXB-AS3 expression was validated in the TCGA AML cohort and another MDS cohort from our institute. The subgroup analyses in MDS patients showed that higher HOXB-AS3 expressions could predict poor prognosis only in lower-risk (median OS, 29.2 months versus 77.3 months, P = 0.0194), but not higher-risk group. CONCLUSIONS: This study uncovers a promoting role of HOXB-AS3 in myeloid malignancies and identifies the prognostic value of HOXB-AS3 expression in AML and MDS patients, particularly in the lower-risk group.

摘要

背景：长链非编码 RNA（lncRNA）代表了细胞转录本的大部分，在造血过程中发挥关键作用。然而，它们在急性髓系白血病（AML）和骨髓增生异常综合征（MDS）中的临床相关性仍知之甚少。在这里，我们研究了位于人类 HOXB 簇的 lncRNA HOXB-AS3 在髓系细胞中的功能，并分析了其在 AML 和 MDS 患者中的预后意义。

方法：使用 shRNA 下调细胞系中的 HOXB-AS3，并通过定量聚合酶链反应评估其效果。通过增殖和 BrdU 流式细胞术来阐明细胞系的增殖情况。此外，我们通过微阵列分析对 193 例 AML 患者和 157 例 MDS 患者进行了 HOXB-AS3 表达的回顾性分析，并评估了其临床重要性。

结果：下调 HOXB-AS3 抑制了细胞增殖。在机制上，HOXB-AS3 增强了细胞周期进展和 DNA 复制中几个关键因子的表达，而不影响 HOX 基因的表达。在 AML 中，HOXB-AS3 表达较高的患者的总生存期（OS）（中位数 OS，17.7 个月与未达到，P < 0.0001；中位无复发生存期，12.9 个月与未达到，P = 0.0070）短于 HOXB-AS3 表达较低的患者。在 MDS 中，HOXB-AS3 表达较高的患者的预后也不如 HOXB-AS3 表达较低的患者（中位数 OS，14.6 个月与 42.4 个月，P = 0.0018）。在 TCGA AML 队列和我们研究所的另一个 MDS 队列中验证了 HOXB-AS3 表达的预后意义。在 MDS 患者的亚组分析中，HOXB-AS3 表达较高仅在低危组（中位数 OS，29.2 个月与 77.3 个月，P = 0.0194），而不是高危组中可以预测不良预后。

结论：本研究揭示了 HOXB-AS3 在髓系恶性肿瘤中的促进作用，并确定了 HOXB-AS3 表达在 AML 和 MDS 患者中的预后价值，特别是在低危组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/bcf251c709cf/12885_2019_5822_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/8765c4d642f4/12885_2019_5822_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/bbd575633579/12885_2019_5822_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/ab6f90b60c9d/12885_2019_5822_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/c89303cc31b6/12885_2019_5822_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/3fee100e1a7f/12885_2019_5822_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/bcf251c709cf/12885_2019_5822_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/8765c4d642f4/12885_2019_5822_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/bbd575633579/12885_2019_5822_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/ab6f90b60c9d/12885_2019_5822_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/c89303cc31b6/12885_2019_5822_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/3fee100e1a7f/12885_2019_5822_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5062/6591843/bcf251c709cf/12885_2019_5822_Fig6_HTML.jpg

相似文献

[1]
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.

BMC Cancer. 2019-6-24

[2]
Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia.

Int J Biol Macromol. 2023-5-15

[3]
Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.

Ann Hematol. 2018-4-13

[4]
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.

Oncotarget. 2016-2-16

[5]
Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.

Biosci Rep. 2019-8-2

[6]
CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.

Clin Exp Med. 2023-12

[7]
LOC101928834, a novel lncRNA in Wnt/β-catenin signaling pathway, promotes cell proliferation and predicts poor clinical outcome in myelodysplastic syndromes.

Clin Sci (Lond). 2020-6-12

[8]
The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.

Oncotarget. 2015-10-13

[9]
lncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression.

Eur Rev Med Pharmacol Sci. 2018-10

[10]
LncRNA HOXB-AS3 promotes growth, invasion and migration of epithelial ovarian cancer by altering glycolysis.

Life Sci. 2021-1-1

引用本文的文献

[1]
MALNC: a new mutant NPM1/IDH2 and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response.

Cancer Gene Ther. 2025-8-23

[2]
NAP1L5 in acute myeloid leukemia: a prognostic biomarker and potential therapeutic target.

Front Oncol. 2025-7-25

[3]
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression.

Nat Commun. 2025-7-1

[4]
Prognostic value of natural killer T cell related genes in acute myeloid leukemia.

Cancer Cell Int. 2025-4-13

[5]
Integrated Computational Analysis Reveals Early Genetic and Epigenetic AML Susceptibility Biomarkers in Benzene-Exposed Workers.

Int J Mol Sci. 2025-1-28

[6]
Molecular leveraging of HOX-embedded non-coding RNAs in the progression of acute myeloid leukemia.

Hum Cell. 2024-11-30

[7]
Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.

Ann Hematol. 2024-8

[8]
Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy.

Front Immunol. 2024

[9]
A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.

Curr Oncol. 2024-4-23

[10]
Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylation.

Cancer Cell Int. 2024-2-22

本文引用的文献

[1]
Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.

Ann Hematol. 2018-4-13

[2]
Expression levels of long non-coding RNAs are prognostic for AML outcome.

J Hematol Oncol. 2018-4-7

[3]
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.

Blood Cancer J. 2018-4-4

[4]
A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Blood Adv. 2017-8-16

[5]
A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth.

Mol Cell. 2017-10-5

[6]
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia.

Oncol Rep. 2017-9

[7]
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017-1-26

[8]
Acute myeloid leukemia: 2016 Update on risk-stratification and management.

Am J Hematol. 2016-8

[9]
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood. 2016-4-11

[10]
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.

Oncotarget. 2016-2-23

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索